Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20)

Annals of General Psychiatry

Volumn 8, Issue , 2009, Pages

  Siamouli, Melina ^a   Moutou, Katerina ^a   Pantoula, Eleonora ^a   Magiria, Stamatia ^b   Chatzivasileiou, Irini ^c   Arapidis, Konstantinos ^d   Chatzivasileiou, Achileas ^e   Deres, Simeon ^a   Fountoulakis, Konstantinos N ^b  

^a Asclepius Mental Clinic   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c General Hospital of Thessaloniki   (Greece)

^d Therapeutirio Spinari Mental Clinic   (Greece)

^e Agios Georgios Mental Clinic   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEPRESSION; EDUCATION; FEMALE; GREECE; HOSPITAL PATIENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL WELL BEING; PSYCHOMETRY; RELIABILITY; SCHIZOPHRENIA; SEX DIFFERENCE; SIMPSON ANGUS SCALE; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC TREATMENT SCALE;

EID: 62149135921     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-8-3     Document Type: Article

References (27)

1. Bobes J Garcia-Portilla MP Bascaran MT Saiz PA Bousono M Quality of life in schizophrenic patients Dialogues Clin Neurosci 2007, 9(2):215-226 17726919
2. Lambert M Naber D Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life CNS Drugs 2004, 18(Suppl 2):5-17 10.2165/00023210-200418002-00002 15461312
3. Hellewell JS Patients' subjective experiences of antipsychotics: clinical relevance CNS Drugs 2002, 16(7):457-471 10.2165/ 00023210-200216070-00003 12056921
4. Awad AG Voruganti LN Heslegrave RJ Hogan TP Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome Int Clin Psychopharmacol 1996, 11(Suppl 2):55-59 10.1097/00004850-199605002-00009 8803661
5. Chue P The relationship between patient satisfaction and treatment outcomes in schizophrenia J Psychopharmacol 2006, 20(6 Suppl):38-56 10.1177/1359786806071246 17046986
6. de Millas W Lambert M Naber D The impact of subjective well-being under neuroleptic treatment on compliance and remission Dialogues Clin Neurosci 2006, 8(1):131-136 16640124
7. Awad AG Voruganti LN Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatry 1999, 45(4):268-275 10.1177/002076409904500405 10689610
8. Santone G Rucci P Muratori ML Monaci A Ciarafoni C Borsetti G Attitudes toward medication in inpatients with schizophrenia: A cluster analytic approach Psychiatry Res 2008, 158(3):324-334 18262656
9. Schmidt P Clouth J Haggenmuller L Naber D Reitberger U Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: Applying structural equation modeling for testing reliability and validity of the index Qual Life Res 2006, 15(7):1191-1202 10.1007/s11136-006-0069-x 17004003
10. Naber D A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables Int Clin Psychopharmacol 1995, 10(Suppl 3):133-138 10.1097/00004850-199509000-00017 8866775
11. Anastasi A Psychological Testing New York: Macmillan Publishing Company 6 1988
12. Altman D Practical Statistics for Medical Research London: Chapman and Hall 1991
13. Balestrieri M Giaroli G Mazzi M Bellantuono C Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients Pharmacopsychiatry 2006, 39(3):81-84 10.1055/ s-2006-941480 16721695
14. Wehmeier PM Kluge M Schacht A Helsberg K Schreiber W Schimmelmann BG Lambert M Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia J Psychiatr Res 2008, 42(8):676-683 10.1016/j.jpsychires.2007.07.005 17720192
15. Naber D Riedel M Klimke A Vorbach EU Lambert M Kuhn KU Bender S Bandelow B Lemmer W Moritz S et al Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia Acta Psychiatr Scand 2005, 111(2):106-115 10.1111/j.1600-0447.2004.00486.x 15667429
16. Hofer A Kemmler G Eder U Edlinger M Hummer M Fleischhacker WW Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects J Clin Psychiatry 2004, 65(7):932-939 15291682
17. Schimmelmann BG Paulus S Schacht M Tilgner C Schulte-Markwort M Lambert M Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics J Child Adolesc Psychopharmacol 2005, 15(2):249-258 10.1089/cap.2005.15.249 15910209
18. Ritsner M Ponizovsky A Endicott J Nechamkin Y Rauchverger B Silver H Modai I The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: A naturalistic study Eur Neuropsychopharmacol 2002, 12(1):31-38 10.1016/S0924-977X(01)00128-6 11788238
19. Dubisar BM Stoner SC Reynolds J Khan R Ramlatchman L Adverse effects of atypical antipsychotic agents and their effects on quality of life Pharmacotherapy 2004, 24(7):843-847 10.1592/phco.24.9.843.36098 15303448
20. Jones PB Barnes TR Davies L Dunn G Lloyd H Hayhurst KP Murray RM Markwick A Lewis SW Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 2006, 63(10):1079-1087 10.1001/archpsyc.63.10.1079 17015810
21. Wehmeier PM Kluge M Schneider E Schacht A Wagner T Schreiber W Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(3):703-712 10.1016/j.pnpbp.2007.01.004 17289237
22. Tempier R Pawliuk N Influence of novel and conventional antipsychotic medication on subjective quality of life J Psychiatry Neurosci 2001, 26(2):131-136 1407744 11291530
23. Karow A Czekalla J Dittmann RW Schacht A Wagner T Lambert M Schimmelmann BG Naber D Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia J Clin Psychiatry 2007, 68(1):75-80 17284133
24. Awad AG Voruganti LN New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry 2004, 49(5):297-302 15198465
25. Pollice R Tomassini A Malavolta M Di Giovambattista E Verni L Roncone R Conti CM Casacchia M Subjective and psychopathological response in patients under different antipsychotic treatments: Are there differences in real clinical practice? J Biol Regul Homeost Agents 2008, 22(1):83-91 18394321
26. de Haan L Weisfelt M Dingemans PM Linszen DH Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome ScaleWouters L Psychopharmacology (Berl) 2002, 162(1):24-28 10.1007/s00213-002-1054-x 12107613
27. de Haan L Nimwegen L Amelsvoort T Dingemans P Linszen D Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia Pharmacopsychiatry 2008, 41(4):125-128 10.1055/s-2008-1076729 18651339